<p> Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the <a class="in-cell-link" href= "https://www.46brooklyn.com/research/2021/12/1/tecfidera" target= "_blank" rel="noopener">full article at 46brooklyn.com</a>.</p>

Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.

<p> Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the <a href="https://www.46brooklyn.com/research/2021/12/1/tecfidera" rel="noopener noreferrer">full article at 46brooklyn.com</a>.</p>

Generic Competition for Dimethyl Fumarate

The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the show provides insights that impact clinical practice and patient care. From the journal Neurology and the American Academy of Neurology, providing education and expert analysis since 2007.

Share Generic Competition for Dimethyl Fumarate

Sign up to save your podcasts

Generic Competition for Dimethyl Fumarate

Generic Competition for Dimethyl Fumarate

More shows like Neurology® Podcast

NEJM This Week

JAMA Clinical Reviews

Practical Neurology Podcast

The Curbsiders Internal Medicine Podcast

JAMA Neurology Author Interviews

Core IM | Internal Medicine Podcast

Neurology Today in 5

Annals On Call Podcast

The Clinical Problem Solvers

Neurology Minute

Harrison's PodClass: Internal Medicine Cases and Board Prep

Neurology Exam Prep Podcast

The Curious Clinicians

Ninja Nerd

Continuum Audio